Poteligeo 4 mg/ml
As listed in the register: Poteligeo 4 mg/ml, Konzentrat zur Herstellung einer Infusionslösung
4 mg/ml ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Mogamulizumabum
- Made by
- Kyowa Kirin Sàrl
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Poteligeo ist indiziert für die Behandlung von erwachsenen Patienten mit rezidivierter oder refraktärer Mycosis fungoides (MF) oder Sézary-Syndrome (SS), welche mindestens eine vorherige Therapie erhalten haben (siehe Abschnitt «Klinische Wirksamkeit»).
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Kyowa Kirin Sàrl |
|---|---|
| Active substance | Mogamulizumabum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 4 mg/ml |
| Classification | L01FX09 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Poteligeo 4 mg/ml, Konzentrat zur Herstellung einer Infusionslösung |
| Packs | 1 Durchstechflasche(n) |
| Zulassungsnummer | 67444 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.